18 research outputs found
Trial flow in the systematic review of long term anticoagulation in patients with cancer and venous thromboembolism
<p><b>Copyright information:</b></p><p>Taken from "Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review"</p><p>http://www.jeccr.com/content/27/1/21</p><p>Journal of Experimental & Clinical Cancer Research : CR 2008;27(1):21-21.</p><p>Published online 18 Jul 2008</p><p>PMCID:PMC2507703.</p><p></p
Inverted funnel plot for randomized controlled trials of parenteral anticoagulation in cancer patients
<p><b>Copyright information:</b></p><p>Taken from "Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review"</p><p>http://www.jeccr.com/content/27/1/4</p><p>Journal of Experimental & Clinical Cancer Research : CR 2008;27(1):4-4.</p><p>Published online 15 May 2008</p><p>PMCID:PMC2438335.</p><p></p
Forest plot of vitamin D supplementation and breast cancer incidence.
<p>Administration mode on treatment effects. Legend to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069269#pone-0069269-g004" target="_blank">Figure 4</a>. M–H, Mantel-Haenszel; 95% CI, 95% confidence interval; df, degrees of freedom.</p
Forest plot of vitamin D supplementation and breast cancer incidence.
<p>Legend to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069269#pone-0069269-g003" target="_blank">Figure 3</a>. M–H, Mantel-Haenszel; 95% CI, 95% confidence interval; df, degrees of freedom.</p
Risk of bias summary.
<p>Legend to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0069269#pone-0069269-g002" target="_blank">Figure 2</a>. Reviewers’ judgment on each “Risk of bias” item within each included study.</p
Characteristics of the included Randomized Clinical Trials (RCTs).
<p>Characteristics of the included Randomized Clinical Trials (RCTs).</p
Additional file 2: Table S2. of Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
associations between TAZ/YAP, assessed in the tumor and in the microenvironment, and clinical-molecular features and pCR (N = 61). (DOCX 12 kb
Additional file 3: Table S3. of Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
Pattern of recurrence in the 19 TNBC patients. (DOCX 12 kb
Additional file 1: Table S1. of Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
Expression of TAZ and YAP in cancer cells, non-lymphocytic stromal cells, endothelial cells, and tumor-infiltrating lymphocytes. Subcellular localization of TAZ/YAP in tumors is also reported (N = 61). (DOCX 13 kb
Representative examples of immunohistochemical expression of DNA damage and repair biomarkers in cervical cancer patients.
<p>Three consecutive sections for each tumor are showed. (A-C) A triple positive tumor with nuclear Îł-H2AX(A), pWee1(B) and pChk1 (C) immunoreactivity.(D-F) A tumor that did not express Îł-H2AX (D), and that co-expressed pWee1(E) and pChk1 (F). (G-I) A tumor expressing nuclear Îł-H2AX (G) that lacked both pWee1(H) and pChk1 (I) expression.</p